Answers are grounded in this paper and cite their sources.
Case report demonstrates extracorporeal hemocorrection's efficacy in blood pressure reduction for refractory arterial hypertension, suggesting new therapeutic approaches.
The particular focus of the modern scientific community and practical medicine is concentrated on patients with refractory arterial hypertension when appropriate lifestyle measures and treatment with optimal or best tolerated doses of 5 or more drugs with diuretic and mineralocorticoid receptor antagonist fail to lower office blood pressure to <140/90 mmHg. Inefficiency of recommended treatment methods requires new therapeutic approaches for these patients. The efficiency and mechanisms of extracorporeal treatment for blood pressure reduction in patients with malignant hypertension were first studied in the 1980s and 1990s. This clinical case study demonstrates the use of extracorporeal hemocorrection procedures as part of the complex treatment of patients with refractory arterial hypertension.
No takes yet. Share an insight, caveat, or question.
Agadzhanyan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: